Table 1. Clinical and genomic characteristics of patients’ treatment based on MTB discussion.
| Patient | Diagnosis | Genomic alteration | MTB recommendation | PFS (months) | Best response |
|---|---|---|---|---|---|
| 1 | NSCLC | EGFR K745-E746ins | Afatinib | 29.25 | SD |
| 2 | NSCLC | GNAS p.Q227L | Trametinib | 10.75 | PD |
| 3 | CRC | ERBB2 | Trastuzumab/pertuzumab | 1.58 | PD |
| 4 | NSCLC | ALK | Alectinib | 38.08 | PR |
| 5 | Pancreatic adenocarcinoma | ATM | Olaparib | 9.67 | PR |
| 6 | Urothelial | STK11 | Everolimus | 1.55 | PD |
| 7 | CRC | BRCA1 | Olaparib | Never done | PR |
| 8 | Ductal carcinoma (breast) | ERBB2 | Trastuzumab Pertuzumab | 13.58 | PD |
| 9 | CUP | KIT | Avapritinib | 17.00 | PD |
| 10 | NSLC | EGFR | Osimertinib | 37.75 | PR |
| 11 | mCRPC | AR amplification | Abiraterone | Never done | PR |
| 12 | NSCLC | ALK fusion | Lorlatinib | 23.83 | PD |
| 13 | CUP | ERBB2 | Trastuzumab/pertuzumab | 15.25 | PD |
| 14 | Ductal carcinoma (breast) | FGF19 amplification | Infigratinib | Never done | SD |
| 15 | Bone sarcoma | FGFR1 amplification | Pazopanib | 7.42 | SD |
| 16 | Cholangiocarcinoma | IDH1 | Ivosidenib | Never done | SD |
| Median PFS: 15.25 months | |||||
NSCLC, Non-small cell lung carcinoma; CRC, Colorectal carcinoma; CUP, Carcinoma of unknown primary; mCRPC, Metastatic castration resistant prostate cancer; SD, Stable disease; PD, Progressive disease; PR, Partial response; PFS, Progression-free survival; AR, androgen receptor.